Current studentsExisting staffContact us
 

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group

Simple item page
dc.contributor.authorRyan, G.
dc.contributor.authorMartinelli, G.
dc.contributor.authorKuper-Hommel, M.
dc.contributor.authorTsang, R.
dc.contributor.authorPruneri, G.
dc.contributor.authorYuen, K.
dc.contributor.authorRoos, D.
dc.contributor.authorLennard, A.
dc.contributor.authorDevizzi, L.
dc.contributor.authorCrabb, S.
dc.contributor.authorHossfeld, D.
dc.contributor.authorPratt, G.
dc.contributor.authorDell'Olio, M.
dc.contributor.authorChoo, S.
dc.contributor.authorBociek, R.
dc.contributor.authorRadford, J.
dc.contributor.authorLade, S.
dc.contributor.authorGianni, A.
dc.contributor.authorZucca, E.
dc.contributor.authorCavalli, F.
dc.contributor.authoret al.
dc.date.issued2008
dc.description.abstractBACKGROUND: Primary diffuse large B-cell lymphoma (DLBCL) of breast is rare. We aimed to define clinical features, prognostic factors, patterns of failure, and treatment outcomes. PATIENTS AND METHODS: A retrospective international study of 204 eligible patients presenting to the International Extranodal Lymphoma Study Group-affiliated institutions from 1980 to 2003. RESULTS: Median age was 64 years, with 95% of patients presenting with unilateral disease. Median overall survival (OS) was 8.0 years, and median progression-free survival 5.5 years. In multifactor analysis, favourable International Prognostic Index score, anthracycline-containing chemotherapy, and radiotherapy (RT) were significantly associated with longer OS (each P ≤ 0.03). There was no benefit from mastectomy, as opposed to biopsy or lumpectomy only. At a median follow-up time of 5.5 years, 37% of patients had progressed—16% in the same or contralateral breast, 5% in the central nervous system, and 14% in other extranodal sites. CONCLUSIONS: The combination of limited surgery, anthracycline-containing chemotherapy, and involved-field RT produced the best outcome in the pre-rituximab era. A prospective trial on the basis of these results should be pursued to confirm these observations and to determine whether the impact of rituximab on the patterns of relapse and outcome parallels that of DLBCL presenting at other sites.
dc.description.statementofresponsibilityG. Ryan, G. Martinelli, M. Kuper-Hommel, R. Tsang, G. Pruneri, K. Yuen, D. Roos, A. Lennard, L. Devizzi, S. Crabb, D. Hossfeld, G. Pratt, M. Dell'Olio, S. P. Choo, R. G. Bociek, J. Radford, S. Lade, A. M. Gianni, E. Zucca, F. Cavalli and J. F. Seymour
dc.identifier.citationAnnals of Oncology, 2008; 19(2):233-241
dc.identifier.doi10.1093/annonc/mdm471
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttp://hdl.handle.net/2440/82417
dc.language.isoen
dc.publisherOxford Univ Press
dc.rights© 2007 European Society for Medical Oncology.
dc.source.urihttps://doi.org/10.1093/annonc/mdm471
dc.subjectAnthracycline-based chemotherapy
dc.subjectbreast
dc.subjectlarge B-cell lymphoma
dc.subjectradiotherapy
dc.titlePrimary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications